

Resource Summary Report

Generated by [RRID](#) on Sep 19, 2026

Fluidigm CyTOF

RRID:SCR_021055

Type: Tool

Proper Citation

Fluidigm CyTOF (RRID:SCR_021055)

Resource Information

URL: <https://www.fluidigm.com/singlearticles/cytof-software-upgrade-7dot0>

Proper Citation: Fluidigm CyTOF (RRID:SCR_021055)

Description: Software for analyzing mass cytometry (CyTOF) data.

Synonyms: CyTOF Software v7.0

Resource Type: data analysis software, data processing software, software application, software resource

Keywords: mass cytometry data analysis, CyTOF, Fluidigm, cytof

Availability: Restricted

Resource Name: Fluidigm CyTOF

Resource ID: SCR_021055

Record Creation Time: 20220129T080353+0000

Record Last Update: 20260912T195950+0000

Ratings and Alerts

No rating or validation information has been found for Fluidigm CyTOF.

No alerts have been found for Fluidigm CyTOF.

Data and Source Information

Source: [SciCrunch Registry](#)

Usage and Citation Metrics

We found 13 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Li Z, et al. (2026) Gemcitabine plus Nivolumab with Carboplatin or Oxaliplatin in Cisplatin-Ineligible Patients with Metastatic Urothelial Carcinoma: A Randomized Phase II Trial. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 32(14), 2911.

Zhou S, et al. (2026) Vascular normalization by erianin unleashes CAR-T immunotherapy in glioblastoma. *Angiogenesis*, 29(2), 18.

Christenson ES, et al. (2025) Nivolumab and Relatlimab for the Treatment of Patients with Unresectable or Metastatic Mismatch Repair-Proficient Colorectal Cancer. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 31(15), 3182.

Semitekolou M, et al. (2025) Blood immunomap for prediction of responses to anti-PD-1 immunotherapy in metastatic non-small cell lung cancer. *iScience*, 28(9), 112804.

Zhao H, et al. (2025) Single-Cell Analysis of Posttranslational Modifications Identifies Immunosuppressive Macrophage Subtypes in the HBV-Positive Hepatocellular Carcinoma Microenvironment. *Cancer immunology research*, 13(8), 1303.

Bj??rnsd OV, et al. (2024) Global and single-cell proteomics view of the co-evolution between neural progenitors and breast cancer cells in a co-culture model. *EBioMedicine*, 108, 105325.

Gonzalez-Kozlova E, et al. (2024) Tumor-Immune Signatures of Treatment Resistance to Brentuximab Vedotin with Ipilimumab and/or Nivolumab in Hodgkin Lymphoma. *Cancer research communications*, 4(7), 1726.

Sperber HS, et al. (2023) The hypoxia-regulated ectonucleotidase CD73 is a host determinant of HIV latency. *Cell reports*, 42(11), 113285.

Hung CN, et al. (2023) AXL-initiated paracrine activation of pSTAT3 enhances mesenchymal and vasculogenic supportive features of tumor-associated macrophages. *Cell reports*, 42(9), 113067.

Gray GK, et al. (2023) Single-cell and spatial analyses reveal a tradeoff between murine mammary proliferation and lineage programs associated with endocrine cues. *Cell reports*, 42(10), 113293.

Harpaz N, et al. (2022) Single-cell epigenetic analysis reveals principles of chromatin states in H3.3-K27M gliomas. *Molecular cell*, 82(14), 2696.

Sklavenitis-Pistofidis R, et al. (2022) Immune biomarkers of response to immunotherapy in patients with high-risk smoldering myeloma. *Cancer cell*, 40(11), 1358.

Schwabenland M, et al. (2021) Deep spatial profiling of human COVID-19 brains reveals neuroinflammation with distinct microanatomical microglia-T-cell interactions. *Immunity*,

54(7), 1594.